Relevium Medical

Relevium Medical is focused on creating an innovative injectable gel designed to alleviate the symptoms of knee osteoarthritis, a prevalent and debilitating condition affecting a significant portion of the population. Currently, individuals suffering from osteoarthritis often require frequent injections and strong oral medications to manage their pain. Due to the progressive nature of the disease, many patients unfortunately become reliant on highly addictive opioid medications.

Relevium Medical has secured $3.7 million in non-dilutive funding and successfully completed preclinical testing. These tests have demonstrated the safety and efficacy of their drug, which selectively targets and blocks nerves responsible for transmitting pain signals, resulting in pain relief that lasts significantly longer than existing treatments.

The market for knee osteoarthritis treatments is substantial. With insurance companies currently covering approximately $770 per six-monthly treatment and an estimated 5 million patients in the US alone, the market opportunity is estimated at $7.7 billion. Furthermore, Relevium Medical's platform biotherapeutic has the potential to be adapted for the treatment of osteoarthritis in other joints, such as the hip and ankle, addressing similar unmet needs in patient care.